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wo Stents, T-Stenting, Trials*
on Waksman, MD, FACC, Laurent Bonello, MD
ashington, DC
ifurcation, the division of an artery into 2 branches, is a
ommon anatomy feature of the human coronary tree and is
ecognized as a common site for atherosclerotic plaque buildup
ue to the differences in coronary flow, turbulence, and shear
tress at the site of the bifurcation. The prevalence of bifurca-
ion stenosis in the human coronary tree is reported to be
etween 15% to 20% of all interventions and is considered
omplex and challenging for percutaneous intervention.
See page 358
Numerous techniques and devices have been proposed to
ddress the treatment of bifurcation lesions: balloon angio-
lasty, metallic stents, drug-eluting stents (DES), newly
esigned stents with dedicated access to the side branch,
nd full bifurcated stents. Clearly, the interest in the
reatment of bifurcation stenting has increased with the
vailability to significantly reduce the recurrence rate, but
his was associated with the increasing fear of stent throm-
osis. Despite this extensive body of work and the latest
nnovations of 2008, there is not a “one size fits all” solution
o the bifurcation puzzle, while the optimal percutaneous
oronary intervention technique remains undetermined.
In this issue of JACC: Cardiovascular Interventions, Rou-
ledge et al. (1) present 2-year outcome data of 477 patients
reated for bifurcation coronary disease with provisional side
ranch T-stenting using DES, and claim a systematic
pproach feasible for 90% of the patients, with acceptable
fficacy and safety profiles. This editorial is written in
esponse to this provocative study and will cover the 5 Ts of
ifurcation stenting: Type of bifurcation, Techniques, Two
tents versus one, T-stenting, and Trial design.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.t
From the Department of Internal Medicine, Division of Cardiology, Washington
ospital Center, Washington, DC.ypes of Bifurcation
art of the complexity in treating bifurcation lesions and
pplying technique standardization is in regard to the numer-
us anatomic patterns of bifurcation stenosis and the lack of
onsistent, reliable methodology. Further, the variations in
natomy, angulations, and location of the disease within the
ifurcation have led to the development of numerous classifi-
ations of bifurcation lesions, with differentiation between
true” bifurcation (both the main and the branch are diseased)
nd “false” bifurcation (either the main or the branch is disease)
ased on angiography. The most popular and intuitive classi-
cation is that of Medina et al. (2), which identifies at least 7
ypes of bifurcation involving the proximal main branch, the
istal main branch, and the side branch, with different varia-
ions. If we add this to the classification of the various potential
ngulations between the main and the side branches, the sizes
f the parent vessel and the side branch, and the different
otential morphologies of the diseased segment (calcification,
brosis, and so on), we can identify nearly endless anatomic
nd morphologic configurations of bifurcations types (3).
echnique
stents versus 1. Numerous techniques have been proposed
or the treatment of bifurcation lesions. The first decision
hat the operator must make is whether the procedure will
nvolve 1 or 2 stents. The most important information
elates to the size of the side branch and the degree of the
isease in this branch. Or do we really care about the side
ranch? Initially, the thought of using 2 stents for all
ifurcated lesions was appealing because this approach
sually resulted in an optimal angiographic success rate.
mong the most popular techniques that employed the use
f 2 stents are the culotte, crush, V-stenting, T-stenting,
nd simultaneous kissing stents (4). However, after numer-
us reports of high rates of late complications, including an
ncrease in stent thrombosis and restenosis frequency, sys-
ematical use of 2 stents did not live up to expectations
5–8). These poor outcomes were observed regardless of the
echnique used and thus discouraged the liberal use of 2
tents. Therefore, the provisional strategy gained ground:
ry 1 stent first, and, if the result is not acceptable (dissec-
ion, impaired lumen, or flow of the other branch), use a
econd stent for the side branch. The superiority of such a
rovisional approach over a 2-stent technique was con-
rmed by the Nordic Bifurcation study (9). The results of
his study had operators favoring the provisional rather than
he 2-stent approach. However, many questions still remain
egarding this approach: can we predict which bifurcation
ill require 2, rather than 1 stent? In how many patients is
he provisional approach feasible? If a second stent is
equired, what then is the optimal technique for implanta-
ion of the second stent? Is provisional stenting still superior
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367o the 2-stent approach with the new generation of stents
vailable? And lastly, are the latest technique modifications,
ncluding pre- and post-kissing, clinically beneficial?
The present study demonstrated that provisional stenting is
easible in 90% of all patients, and those who received a second
tent in the side branch, 28%, had similar long-term outcomes
s those treated with 1 stent. The outcome of this study is
imilar to that of the Nordic Bifurcation study, which observed
o difference in outcomes at 6 months’ follow-up between 1
nd 2 stents (9). Finally, the latest Nordic Bifurcation Stent
echnique study, comparing the culotte and crush techniques,
eported low rates of angiographic restenosis and major adverse
ardiac events for both techniques (10), with similar angio-
raphic and clinical outcomes as the provisional approach with
-stenting reported in the Routledge et al. study (1). This
eaves us with the question of whether, in 2008, provisional
tenting is still superior to 2 stents when an improved tech-
ique is applied and new-generation stents are used?
-stenting. Use of the provisional T-stenting technique is
aining interest because of its simplicity and subsequent
eports of good mid-term outcomes (11–13). As illustrated
n the present report by Routledge et al. (1), it is feasible in
large majority of patients and is associated with low rates
f recurrent events during long-term follow-up. In the past,
he technique was described to resolve dissections of a side
ranch (8) or as a new technique for the use of 2 stents for
he treatment of bifurcation lesions (11). In the present
tudy, the authors used provisional T-stenting as the default
echnique. From a technical point of view, provisional
-stenting offers several advantages compared with other
ifurcation techniques: it is simple to perform in most cases,
nd it limits the need for a second stent, as illustrated by the
ow rate of stenting in the side branch in the present study.
ne technical aspect of the procedure remains in question:
s kissing post-procedure mandatory in the provisional
-stenting approach with 1 or 2 stents? Bench testing
bserved that the final kissing balloon may have several
nteresting advantages: it opens the stent cells to the side
ranch, it allows the side branch ostium to be at least
artially covered by stent struts, and it prevents the main
ranch stent from becoming deformed by side branch
ilation. Further, in previous studies involving crush stent-
ng, kissing balloon was shown to be critical in preventing
estenosis (14). Nevertheless, the clinical impact of a final
issing balloon in provisional T-stenting must be estab-
ished in future trials. Several limitations should be consid-
red with T-stenting: it is not applicable for all lesions, it is
ependent on the bifurcation angle and cannot be applied to
ngles 40°; the second stent, if needed, may not be able to
ully cover the ostium, which will result in switching to a
ini-crush technique, and like other techniques, there is a
earning curve. Nevertheless, among today’s available options,
he provisional T-stenting technique seems to be the simplest
nd is associated with favorable long-term outcomes. srials
erhaps the most challenging component in bifurcation stent-
ng is how to design a clinical trial that will determine the
ptimal treatment strategy. The variability in anatomy, mor-
hology, technique, and learning curve makes it almost impos-
ible to have a reproducible and reliable trial free of deviation
hat can detect the preferred strategy. Even when the same
trategy is performed by the same operator, we find it is hard
o draw definitive conclusions perhaps due to bias in case
election. In the Nordic Bifurcation study, provisional stenting
as superior to the 2-stent strategy, but in the Nordic Bifur-
ation Stent Technique study, either of the 2-stent tech-
iques—crush or culotte—demonstrated excellent results
hen compared with the historical provisional group. A
hallenge in trial design is extending it for the evaluation of
edicated bifurcated stents. Which should be the control
ethod—provisional stenting or the 2-stent technique?
Since in bifurcation stenting one size does not fit all, it is
ossible that several strategies will result in a similar
utcome. We propose revisiting this to test these new
echniques and dedicated bifurcated stents against objective
erformance criteria (OPC) that is set based on existing
ata derived from techniques and devices already used for
ifurcation stenting (15–20) (Table 1). We recognize that
esting a device or a strategy against OPC is subjected to
otential bias in case selection and will have to apply to
road inclusion exclusion criteria as was performed in the
tudy of Routledge et al. (1). A cautionary note and critical
ppraisal should be applied to single-center studies that may
ot be generalized for the rest of the interventional com-
unity and should not be sufficient to serve as a sole
eference for OPC trials. Another difficulty is to determine
he end points of such as study; clinical end points,
ncluding late stent thrombosis, will require large sample
izes, and angiographic surrogates such as late loss can be
one only against the parent vessel and not to the side
ranch when the provisional stent control group is chosen.
erhaps it would be better to choose a composite of clinical
vent end points, including both the parent and the branch
essel failure, to be used for the OPC. This approach could
ave been used in the present manuscript to assess the
easibility and safety of provisional T-stenting.
Bifurcation stenting continues to challenge the interven-
ional cardiologist in 2008. Despite the recent literature,
ncluding the present manuscript, there is a lack of consen-
us on an array of important issues, such as: Which branches
eserve protection? Should provisional stenting be the
efault strategy of bifurcation stenting? Should we always
re-dilate the side branch? And if 2 stents are required,
hich technique would be the best? Is kissing always
andatory for both branches? Are DES more thrombo-
enic? And finally, how will the special dedicated bifurcated
tents be integrated into current practice? With further trials
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368nd perhaps the sixth T in bifurcation stenting (Time), the
nswers to these important questions will be answered.
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ngton, DC 20010. E-mail: ron.waksman@medstar.net.
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et al.
(15)
Gunnes
et al.
(10)
Routledge
et al.
(1)
205 200 413 281 424 477
SES/PES SES SES SES/PES SES SES/PES
1
provisional
2 1 vs. 2 2 2 1
provisional
T-stenting SKS n/a Crush Culotte Crush Provisional
T-stenting
46 n/a 53 50.6 Crush 88.8
Culotte 93.9
95.4
24 9  2 6 9 8 24
8.3 4 1.5 9.7 n/a 5.2
n/a n/a 2 11 n/a 8.9
0.5 1 0.2 4.3 n/a 3.6
1.5 2 1.2 1.3 n/a 5.4
2.4 4 0.2 9.2 n/a 1.8
17.6 9 3.1 16.5 Crush 4.3
Culotte 3.7
13.7
clitaxel-eluting stent(s); SES sirolimus-eluting stent(s); SKS simultaneous kissing stents; TLRTsuchi
et al
(20)
324
SES
n/a
n/a
n/a
12
n/a
n/a
1.5
0.9
5.9
13.3
ES paluting stents  stent thrombosis.
